CN101918360A - 具有1-磷酸-鞘氨醇(s1p)受体生物学活性的带芳基或者杂芳基基团的吲哚化合物 - Google Patents

具有1-磷酸-鞘氨醇(s1p)受体生物学活性的带芳基或者杂芳基基团的吲哚化合物 Download PDF

Info

Publication number
CN101918360A
CN101918360A CN2008801163102A CN200880116310A CN101918360A CN 101918360 A CN101918360 A CN 101918360A CN 2008801163102 A CN2008801163102 A CN 2008801163102A CN 200880116310 A CN200880116310 A CN 200880116310A CN 101918360 A CN101918360 A CN 101918360A
Authority
CN
China
Prior art keywords
group
heteroaryl
substituted
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801163102A
Other languages
English (en)
Chinese (zh)
Inventor
R·L·比尔德
袁海卿
J·E·唐奈罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN101918360A publication Critical patent/CN101918360A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2008801163102A 2007-09-24 2008-09-18 具有1-磷酸-鞘氨醇(s1p)受体生物学活性的带芳基或者杂芳基基团的吲哚化合物 Pending CN101918360A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97451107P 2007-09-24 2007-09-24
US60/974,511 2007-09-24
PCT/US2008/076792 WO2009042485A1 (en) 2007-09-24 2008-09-18 Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity

Publications (1)

Publication Number Publication Date
CN101918360A true CN101918360A (zh) 2010-12-15

Family

ID=40042883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801163102A Pending CN101918360A (zh) 2007-09-24 2008-09-18 具有1-磷酸-鞘氨醇(s1p)受体生物学活性的带芳基或者杂芳基基团的吲哚化合物

Country Status (10)

Country Link
US (1) US7888336B2 (enExample)
EP (1) EP2203424A1 (enExample)
JP (1) JP2010540543A (enExample)
KR (1) KR20100067677A (enExample)
CN (1) CN101918360A (enExample)
AU (1) AU2008304657B2 (enExample)
BR (1) BRPI0817397A2 (enExample)
CA (1) CA2700539A1 (enExample)
RU (1) RU2010112275A (enExample)
WO (1) WO2009042485A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781766A (zh) * 2011-04-18 2014-05-07 阿勒根公司 用作鞘氨醇-1磷酸酯受体调节剂的取代的双环甲胺衍生物
CN108699037A (zh) * 2016-03-04 2018-10-23 加拉帕戈斯股份有限公司 用于治疗纤维化的新化合物及其药物组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1849465A4 (en) * 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
US8524917B2 (en) * 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
EP0146810A3 (de) 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
NZ233285A (en) 1989-04-18 1992-06-25 Duphar Int Res Imidazole-substituted carbamoyl-indoles and condensed analogues thereof and pharmaceutical compositions
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5811425A (en) * 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
WO1998040349A1 (en) 1997-03-12 1998-09-17 Takara Shuzo Co., Ltd. Sphingosine analogues
AU9002298A (en) 1997-09-11 1999-03-29 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
FR2814073B1 (fr) * 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition
ES2290318T3 (es) 2001-06-20 2008-02-16 Wyeth Derivados sustituidos de acido indolico como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP1594508B1 (en) 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
AU2004234066B2 (en) 2003-04-30 2008-02-21 Novartis Ag Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
KR20080102181A (ko) * 2006-02-15 2008-11-24 알러간, 인코포레이티드 스핑고신-1-포스페이트 (에스1피) 수용체 길항제 생물학적 활성을 갖는 아릴 또는 헤테로아릴기를 포함하는 인돌-3-카르보실산 아미드, 에스테르, 티오아미드 및 티올 에스테르 화합물
WO2007112322A2 (en) 2006-03-28 2007-10-04 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781766A (zh) * 2011-04-18 2014-05-07 阿勒根公司 用作鞘氨醇-1磷酸酯受体调节剂的取代的双环甲胺衍生物
CN108699037A (zh) * 2016-03-04 2018-10-23 加拉帕戈斯股份有限公司 用于治疗纤维化的新化合物及其药物组合物

Also Published As

Publication number Publication date
WO2009042485A1 (en) 2009-04-02
BRPI0817397A2 (pt) 2015-04-07
US20100240614A1 (en) 2010-09-23
RU2010112275A (ru) 2011-11-10
CA2700539A1 (en) 2009-04-02
AU2008304657A1 (en) 2009-04-02
US7888336B2 (en) 2011-02-15
AU2008304657B2 (en) 2013-09-05
EP2203424A1 (en) 2010-07-07
JP2010540543A (ja) 2010-12-24
KR20100067677A (ko) 2010-06-21

Similar Documents

Publication Publication Date Title
ES2970938T3 (es) Activadores de piruvato quinasa para uso en terapia
KR0139626B1 (ko) 강심제
EP1988898A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
US8729062B2 (en) Benzyl azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
CN101918360A (zh) 具有1-磷酸-鞘氨醇(s1p)受体生物学活性的带芳基或者杂芳基基团的吲哚化合物
ES2515415T3 (es) Derivados de 3-(4-((1H-imidazol-1-il)metil)fenil)-5-aril-1,2,4-oxadiazol como moduladores de receptores de la esfingosina-1-fosfato
CN103370102A (zh) 作为鞘氨醇1-磷酸(s1p)受体调节的新型肟衍生物
US8492410B2 (en) Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
RU2212237C2 (ru) Средство для лечения нейрогенного воспаления
US8143291B2 (en) Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity
MXPA02003452A (es) Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica.
HUP0000768A2 (hu) Szubsztituált benzo[1,4]dioxánok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
JPWO2003061700A1 (ja) 慢性腎疾患治療薬
JPWO2003068263A1 (ja) 高血圧症治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101215